GSK Settles With N.Y.; Company Will Post Past Trial Data By End Of 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
The settlement includes a modest $2.5 mil. disgorgement fee. GSK is also required to advertise the clinical trial register in seven prominent peer reviewed journals.
You may also be interested in...
PhRMA Clinical Trial Code: Disclosure Edition
The Pharmaceutical Research and Manufacturers of America is committing its members to disclose a broader array of clinical trials as a means to defend the corporate-sponsored clinical development process against continuing charges of bias and against the erosion of public trust
PhRMA Clinical Trial Code: Disclosure Edition
The Pharmaceutical Research and Manufacturers of America is committing its members to disclose a broader array of clinical trials as a means to defend the corporate-sponsored clinical development process against continuing charges of bias and against the erosion of public trust
PhRMA Clinical Trial Code: Disclosure Edition
PhRMA is using broad disclosure as a defense against questions of clinical trial bias. Disclosure used to be a penalty forced on firms in consent decrees and lawsuits; now it appears as a pillar to building trust for corporate-sponsored trials.